SARS-CoV-2 Mutations: An Insight

Phartyal, Rajendra; Verma, Mansi

doi:10.1007/978-3-030-71165-8_25

Cited by 1 publication

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This local outbreak of the novel coronavirus disease (COVID-19) spread like wildfire within a short period of time, crippling Europe and other continents, and, on 11 March 2020, COVID-19 was characterized as a pandemic by the WHO. It is caused by a novel human pathogen SARS-CoV-2 from the Coronaviridae family [1,2]. The global spread and high virulence of this virus has led to the appearance of many variants in various geographical locations.…”

Section: Introductionmentioning

confidence: 99%

Changing Dynamics of SARS-CoV-2: A Global Challenge

et al. 2022

View full text Add to dashboard Cite

Since November 2019, SARS-CoV-2 has been a matter of global concern due to its rapid spread, the millions of deaths it caused, and repeated waves of infections. One after another, many variants of this novel virus have come into existence due to its constant mutability, specifically in the spike glycoprotein region. The tally for variants of concern (VOCs), which already include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2), has increased to five with the latest appearance of Omicron (B.1.1.529). In our study, we examine the effect of the transmissibility and infectious potential of the virus due to various mutations of SARS-CoV-2, especially in the receptor-binding domain (RBD). We discuss the role of genome sequencing in tracing all the mutations and the importance of the R value (reproductive number) to understand the virus spread. We also review the effectiveness of the available vaccines on the variants of concern, as the rapid spread of the newly emergent Omicron variant has raised doubts about the usefulness of the current vaccines. The use of a mixed vaccination strategy has proved to be effective, yet the newer variants, such as Omicron, demand booster doses for the population. Multivalent immunogens could be considered as the plausible solution for conferring protection against potential new mutants of the virus in the future.

show abstract

Section: Introductionmentioning

confidence: 99%